Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Mette Tiedemann Skipper und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmar…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Metabolic Syndrome, Blood Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Danish Cancer Research Foundation, NordForsk, Engineer Otto Christensen's Foundation.
Abstract (Originalsprache)
Background
Metabolic syndrome (MetS), a risk factor for early cardiovascular morbidity and mortality, is seen in up to 34% of survivors of childhood acute lymphoblastic leukemia (ALL). Procedure We performed a Danish, national cross‐sectional study of ALL survivors (aged 1–45 years at diagnosis) treated according to the NOPHO ALL2008 protocol, examined at least 1 year after treatment cessation. The study included non‐cancer community controls, matched on sex and age. We explored the prevalence and components of the MetS criteria (hyperglycemia, hypertension, increased waist circumference (WC), and dyslipidemia) and glucose homeostasis (insulin and C‐peptide).
Results
We included 366 survivors of ALL (participation rate 84%) and 368 controls. Median age (IQR) at follow‐up examination was 14.1 (10.8–21.8) years, and follow‐up time after the ALL diagnosis was 6.9 (4.7–9.1). The prevalence of MetS in survivors was 7.6% and in controls 3.8 % ( p = 0.039). The increased MetS prevalence was driven by ALL patients undergoing total body irradiation (TBI), and age and body mass index (BMI) percentile ≥95 at diagnosis ( p ≤ 0.01). The MetS prevalence in non‐TBI patients did not differ from controls ( p = 0.43), but non‐TBI patients more often fulfilled the MetS criteria WC and/or elevated high‐density lipoprotein ( p < 0.03). Survivors had higher serum insulin and C‐peptide than controls ( p < 0.01).
Conclusions
ALL survivors have an increased risk of MetS compared with controls, essentially driven by the patients treated with TBI. The MetS frequency in non‐TBI patients is equal to controls, but non‐TBI patients more often have one or two components of Mets. ALL survivors seem slightly more insulin‐resistant than controls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital-Herlev, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Mette Tiedemann Skipper, Kjeld Schmiegelow, Thomas Leth Frandsen, Birgitte Klug Albertsen
Förderung
- The Danish Cancer Research Foundation
- NordForsk
- Engineer Otto Christensen's Foundation
- Riisford Foundation
- Merchant M. Brogaard and wife's Memorial Foundation
- Aase and Ejnar Danielsen's Foundation
- Health Research Foundation of Central Denmark Region
- Aarhus University
Zitieren
APA
Skipper, M. T., Birkebæk, N., Jensen, R. B., Langdahl, B. L., Tuckuviene, R., Wehner, P. S., Schmiegelow, K., Frandsen, T. L., Andrés-Jensen, L., & Albertsen, B. K. (2025). Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31705
Vancouver
Skipper MT, Birkebæk N, Jensen RB, Langdahl BL, Tuckuviene R, Wehner PS, et al. Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31705
BibTeX
@article{Skipper2025,
author = {Skipper, Mette Tiedemann and Birkebæk, Niels and Jensen, Rikke Beck and Langdahl, Bente Lomholt and Tuckuviene, Ruta and Wehner, Peder Skov and Schmiegelow, Kjeld and Frandsen, Thomas Leth and Andrés-Jensen, Liv and Albertsen, Birgitte Klug},
title = {Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31705}
}
EUVIMED